Warning: The NCBI web site requires JavaScript to function. more...
Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis.
Awadzi K.
Filaria J. 2003 Oct 24;2 Suppl 1:S6.
Related citations
Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.
Scientific Working Group on Serious Adverse Events in Loa Loa endemic areas.
Filaria J. 2003 Oct 24;2 Suppl 1:S2.
Programmatic and Communication Issues in Relation to Serious Adverse Events Following Ivermectin Treatment in areas Co-endemic for Onchocerciasis and Loiasis.
Haselow NJ, Akame J, Evini C, Akongo S.
Filaria J. 2003 Oct 24;2 Suppl 1:S10.
Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future.
Twum-Danso NA.
Filaria J. 2003 Oct 24;2 Suppl 1:S7.
Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.
Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP.
Filaria J. 2003 Oct 24;2 Suppl 1:S4.
Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases.
Filaria J. 2003 Oct 24;2 Suppl 1:S3.
Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.
Mackenzie CD, Geary TG, Gerlach JA.
Filaria J. 2003 Oct 24;2 Suppl 1:S5.
Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
Cates CJ, Lasserson TJ, Jaeschke R.
Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006922. Review.
Onchocerciasis control: biological research is still needed.
Boussinesq M.
Parasite. 2008 Sep;15(3):510-4. Review.
Mass treatment of onchocerciasis with ivermectin: should people with epilepsy and/or growth-retardation syndromes be excluded?
Ann Trop Med Parasitol. 2004 Mar;98(2):99-114. Review.
[Retinal hemorrhages after ivermectin treatment for onchocerciasis in a patient with Loa loa microfilaremia].
Moussala M, Fobi G, Ongolo Zogo P, Bella Hiag LA, Bengono G, McMoli TE.
J Fr Ophtalmol. 2004 Jan;27(1):63-6. French.
[Ivermectin].
Med Trop (Mars). 2005;65(1):69-79. Review. French.
Overview: Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.
Duke BO.
Filaria J. 2003 Oct 24;2 Suppl 1:S1. No abstract available.
The Mectizan Donation Program (MDP).
Thylefors B.
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:39-44.
Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events.
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006924. Review.
Control of onchocerciasis.
Boatin BA, Richards FO Jr.
Adv Parasitol. 2006;61:349-94. Review.
Combined Utilisation of Rapid Assessment Procedures for Loiasis (RAPLOA) and Onchocerciasis (REA) in Rain forest Villages of Cameroon.
Wanji S, Tendongfor N, Esum M, Yundze SS, Taylor MJ, Enyong P.
Filaria J. 2005 Apr 7;4(1):2.
Adverse reactions to the ivermectin treatment of onchocerciasis patients: does infection with the human immunodeficiency virus play a role?
Kipp W, Bamhuhiiga J, Rubaale T, Kabagambe G.
Ann Trop Med Parasitol. 2005 Jun;99(4):395-402.
Regular treatment with formoterol for chronic asthma: serious adverse events.
Cates CJ, Cates MJ, Lasserson TJ.
Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006923. Review.
Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ, McCormack PL.
CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on